Organic anion transporting polypeptide 1B3 (OATP1B3) is a major influx transporter mediating the hepatic uptake of various endogenous substrates as well as clinically important drugs such as statins and anticancer drugs. However, molecular mechanisms controlling the membrane trafficking of OATP1B3 have been largely unknown. Several reports recently indicated the presence of a distinct, cancer-type OATP1B3 variant lacking the N-terminal 28 amino acids compared to OATP1B3 expressed in nonmalignant hepatocytes. Interestingly, the cancer-type OATP1B3 variant is located predominantly in the cytoplasm, implicating the involvement of the N-terminal region of OATP1B3 in its membrane trafficking. In the current study, we set out to experimentally validate the importance of the N-terminal region of OATP1B3 and to identify responsible sequence motif(s) in that region. A number of truncation or point mutants of OATP1B3 were transiently expressed in HEK293T, HCT-8 or MDCK II cells and their expression in cytoplasmic and surface membrane fractions were analyzed by immunoblotting. Our results indicated that the N-terminal sequence of OATP1B3, in particular, at the amino acid positions between 12 and 28, may be indispensable in its membrane trafficking. Moreover, our results using a fusion construct indicated that the first 50 amino acids of OATP1B3 are sufficient for its membrane localization. The importance of the N-terminal region in membranous localization was shared among the other OATP1B subfamily members, OATP1B1 and rat Oatp1b2. Our efforts to identify the responsible amino acid(s) or structure motif(s) in the N-terminal region did not pinpoint individual amino acids or motifs with putative secondary structures. Our current findings however demonstrate that the N-terminal region is important for the membrane localization of the OATP1B subfamily members and should facilitate future investigations of the mechanisms involved in the regulation and membrane trafficking of these important transporter proteins.
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Organic anion transporting polypeptide 1B3 (OATP1B3) is a major influx transporter mediating the hepatic uptake of various endogenous substrates as well as clinically important drugs such as statins and anticancer drugs. However, molecular mechanisms controlling the membrane trafficking of OATP1B3 have been largely unknown. Several reports recently indicated the presence of a distinct, cancer-type OATP1B3 variant lacking the N-terminal 28 amino acids compared to OATP1B3 expressed in nonmalignant hepatocytes. Interestingly, the cancer-type OATP1B3 variant is located predominantly in the cytoplasm, implicating the involvement of the N-terminal region of OATP1B3 in its membrane trafficking.
In the current study, we set out to experimentally validate the importance of the N-terminal region of OATP1B3 and to identify responsible sequence motif(s) in that region. A number of truncation or point mutants of OATP1B3 were transiently expressed in HEK293T, HCT-8 or MDCK II cells and their expression in cytoplasmic and surface membrane fractions were analyzed by immunoblotting. Our results indicated that the N-terminal sequence of OATP1B3, in particular, at the amino acid positions between 12 and 28, may be indispensable in its membrane trafficking. Moreover, our results using a fusion construct indicated that the first 50 amino acids of OATP1B3 are sufficient for its membrane localization. The importance of the N-terminal region in membranous localization was shared among the other OATP1B subfamily members, OATP1B1 and rat Oatp1b2. Our efforts to identify the responsible amino acid(s) or structure motif(s) in the N-terminal region did not pinpoint individual amino acids or motifs with putative secondary structures. Our current findings however demonstrate that the N-terminal region is important for the membrane localization of the OATP1B subfamily members and should facilitate future investigations of the mechanisms involved in the regulation and membrane trafficking of these important transporter proteins. Ó 2017 Elsevier Inc. All rights reserved.
Introduction
The organic anion transporting polypeptides (OATP; gene symbol SLCO for human, Slco for rodents) represent an important superfamily of solute carriers responsible for the handling of various endogenous and xenobiotic substrates. Based on their amino acid sequence identity, the human and rodent OATPs cluster into 6 families (OATP1 to OATP6) which are further divided into subfamilies. In humans, eleven functional OATPs have been identified with different tissue expression and substrate selectivity profiles. Among them, the OATP1 family members (OATP1A2, OATP1B1, OATP1B3 and OATP1C1) are most extensively investigated for their roles in the disposition of hormonal conjugates, toxins and clinically important drugs such as lipid-lowering statins and anticancer drugs [1, 2] .
It is generally considered that solute transport by OATPs can be bi-directional and occurs in a sodium-and ATP-independent http://dx.doi.org/10.1016/j.bcp.2017.02.013 0006-2952/Ó 2017 Elsevier Inc. All rights reserved.
Abbreviations: OATP1B3, organic anion transporting polypeptide 1B3; OATP1B3-WT, organic anion transporting polypeptide 1B3-wildtype; OATP1B3-D28, organic anion transporting polypeptide 1B3 lacking the N-terminal 28 amino acids; CK-2, casein kinase-II; PKC, protein kinase C.
manner, but the driving force of OATP-mediated transport is not fully understood and remains controversial [3] . Structurally, OATPs are predicted to have 12 transmembrane domains with the N-and C-terminal ends located in the cytoplasm and a large fifth extracellular loop [3] . Several important mechanisms regulating the trafficking and function of OATPs have been reported, including post-translational modifications such as N-glycosylation and protein kinase-mediated phosphorylation [4] [5] [6] . In some members of the OATP family, the PDZ consensus binding sites in their C-terminal regions are shown to play an important role in their subcellular localization and function [7, 8] . For example, human OATP1A2 was shown to have a PDZ-binding domain near its C-terminus and to directly interact with PDZK1 and NHERF1 [8] . However, the two important members of the OATP1B subfamily, OATP1B1 and OATP1B3 contain no PDZ consensus sequences and the regulatory mechanisms for their subcellular localization remain largely unknown [7, 8] .
OATP1B3 (encoded by SLCO1B3) is normally expressed on the basolateral membrane of human hepatocytes and mediates the influx of endogenous (e.g., cholecystokinin octapeptide, estradiol-17-glucuronide, thyroid hormones) and xenobiotic substrates (e.g., pravastatin, rosuvastatin, methotrexate, rifampicin, docetaxel) [9] . Several reports have also indicated that OATP1B3 is frequently expressed in cancer cells developed in multiple organs where OATP1B3 is not present in non-malignant settings [9, 10] . Subsequent investigations revealed that cancer cells express an alternative transcript which translates into a protein lacking the N-terminal 28 amino acids (cancer-type OATP1B3, OATP1B3-D28) compared to the OATP1B3 protein expressed in nonmalignant liver (wildtype OATP1B3, OATP1B3-WT) [11] [12] [13] . Given that the OATP1B3-D28 protein is predominantly located in the cytoplasm of cancer cells [11] , the N-terminal region of OATP1B3-WT has been implicated to regulate its membrane trafficking, but with no experimental validation so far.
Here, we confirmed the importance of the N-terminal region of OATP1B3 in determining its subcellular localization. Using the mutation or fusion constructs of OATP1B3, OATP1B1, or rat Oatp1b2, our results support that the importance of N-terminal regions in plasma membrane trafficking is conserved among these OATP1B subfamily members. Our efforts to identify responsible elements however did not pinpoint individual amino acids or structural motifs. Taken together, our current results suggest that a complex interplay involving the N-terminal region may be in place for the regulation of the trafficking of OATP1B3 and its closely related transporter proteins. Various in silico prediction algorithms were utilized to predict potential amino acid residue(s)/motif(s) in the N-terminal region of OATP1B3 that may be involved in post-translational modifications and secondary structure formation (e.g., a-helix, b-turn), thereby in cellular signaling and processing of OATP1B3. The following in silico algorithms were employed; PROSITE (http:// prosite.expasy.org/) [14] , KinasePhos (http://kinasephos.mbc.nctu. edu.tw/) [15] , BetaTPred (http://imtech.res.in/raghava/betatpred/) [16] , and Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2/) [17] . The relative propensity to form b-turns (D-scores) was assessed using a predictive method previously reported by Chou et al. [18] .
Materials and methods

Cell lines, reagents and antibodies
2.3. Construction of expression plasmids for OATP1B3 harboring truncation, point mutations, or fusion proteins including only the N-terminal region of OATP1B3, OATP1B1 or rat Oatp1b2
The OATP1B3 constructs with the N-terminal region truncated (denoted as D11, D23 and D28) were generated by replacing a corresponding sequence of the previously used C-terminal myctagged expression plasmid (OATP1B3-WT-Myc/pCMV6-Entry) with the incrementally truncated sequences which were PCR amplified with specific primers introducing restriction enzyme sites for SgfI and PacI [11] . For the amino acid residues predicted to have the potential to be involved in cellular signaling or secondary structures, point mutations (to Ala or Pro) were introduced to OATP1B3-WT-Myc/pCMV6-Entry via site-directed mutagenesis (QuikChange Ò Lightning site-directed mutagenesis, Agilent Technologies, Santa Clara, CA, USA). The mutated sequences were subcloned into the non-manipulated pCMV6-Entry vector to eliminate the possibility of any unintended mutations. Direct sequencing was performed to verify the introduction of the intended point mutation. The C-terminal myc-fusion constructs containing only the N-terminal 50 amino acids of OATP1B3, OATP1B1 or rat Oatp1b2 were generated using a similar approach.
Cell surface biotinylation and immunoblotting analyses
Cells were plated at a density of 8 Â 10 5 cells/well on a 6-well culture plate coated with poly-L-lysine and subjected to transient transfection with the corresponding plasmids. Twenty-four hours after transfection, total cell lysates or fractionated samples were prepared as reported previously [11] . Briefly, cells were incubated with the membrane-impermeable labeling agent sulfo-NHS-SSbiotin (1 mg/mL, ThermoFisher Scientific) and subsequently washed with ice-cold PBS containing glycine (100 mM) to remove the extra labeling agent. Cells were lysed with lysis buffer (10 mM Tris, 150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, pH 7.4) containing protease inhibitors (Complete Ò , Roche). Total lysates obtained after removing cell debris by brief centrifugation were incubated with streptavidin agarose beads (ThermoFisher Scientific). After centrifugation, the supernatant (cytoplasmic fraction) and pellet (surface membrane fraction obtained by incubating with Laemmli buffer for 30 min at room temperature) were obtained and subjected to immunoblotting analyses.
Fractionated proteins were resolved by 7.5% or 14% SDSpolyacrylamide gel electrophoresis and subsequently transferred onto polyvinylidene difluoride (PVDF) membranes using a semidry transfer system (Bio-Rad). After blocking for 2 h using 5% skim milk in TBST (0.05% Tween-20 in PBS), the membranes were incubated overnight at 4°C with primary antibodies: myc tag, b-actin, Na + /K + ATPase (1:1000). Immunoreactive bands were visualized by incubating the blots with secondary antibodies conjugated with horseradish peroxidase and using an enhanced chemiluminescence substrate (SuperSignal Ò , ThermoFisher Scientific). b-Actin and Na + /K + ATPase were used as controls to verify equivalent protein loading and enrichment of cytoplasmic and surface membrane fractions, respectively.
Immunofluorescence imaging
HEK293 cells were plated onto 4 chamber culture slides and subsequently transfected with the corresponding N-terminal truncation mutants of myc-tagged OATP1B3. Twenty-four hours after transfection, cells were fixed with 4% paraformaldehyde in icecold PBS for 30 min. The transfected cells were permeabilized with PBS containing 0.3% Triton X-100 for 20 min at room temperature and blocked using PBS containing 2% BSA for 1 h at room temperature. The cells were incubated with a myc tag antibody, followed by a secondary antibody conjugated to Alexa Fluor 488 (Invitrogen). Nuclear DNA was stained using DAPI (Vector Laboratories Inc., Burlingame, CA, USA). The immunofluorescence imaging was obtained using a confocal microscope (Leica TCS SP5).
Transport activity assay using fluorescein as a probe substrate
In order to assess the transport activities of the sequentially truncated mutants of OATP1B3, intracellular retention of fluorescein, a probe substrate for OATP1B3, was measured in HEK293T cells transiently transfected with the corresponding expression plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Twenty-four hours following transfection, cells were preincubated with pre-warmed Opti-MEM for 10 min and subsequently incubated with the media containing sodium fluorescein to be linear) in the presence or absence of rifampicin (100 lΜ, an OATP inhibitor). After washing three times with ice-cold Dulbecco's phosphate buffered saline (DPBS), cells were lysed using 0.5% Triton X-100 solution and intracellular retention of fluorescein was measured using SpectraMax M5 (Molecular Devices, CA, USA) and excitation/emission wavelengths of 460 and 515 nm, respectively. Total protein amount was quantified using the BCA protein assay (ThermoFisher Scientific, Waltham, MA, USA) and used for normalization.
Results
OATP1B3 lacking its N-terminal region (OATP1B3-D28) is located mainly in the cytoplasm
Imai et al. [13] reported that cancer-type OATP1B3 (OATP1B3-D28) is located on the surface membrane of HEK293 cells, different from our previous results using HCT-8 cells [11] . We thus investigated whether these apparent discrepancies are due to differences in cell line models used. Three different cell line models (HCT-8, MDCK II and HEK293T) were transiently transfected with the C-terminal myc-tagged expression plasmid for OATP1B3-WT or OATP1B3-D28 (Fig. 1) . To verify equivalent protein loading and enrichment of cytoplasmic and surface membrane proteins in the respective fractions, the immunoreactive bands for Na [19] . While the immunoreactive bands were readily detected in both cytoplasmic and surface fractions of cells transiently expressing OATP1B3-WT, the immunoreactive bands of OATP1B3-D28 were detected mainly in the cytoplasmic fractions, but barely detectible in the surface fractions (detectable only after a prolonged exposure, data not shown).
3.2. N-terminal truncation mutants of OATP1B3 lacking amino acid residues 12-28 display predominant expression in the cytoplasm
As shown in Fig. 2A , we prepared sequentially truncated mutants of OATP1B3, denoted as D11, D23, and D28. The results from immunofluorescence staining indicated that both OATP1B3-WT and -D11 were located mainly on the surface membrane (Fig. 2B) . On the other hand, OATP1B3-D23 and -D28 displayed a diffuse, cytoplasmic expression pattern. The results from immunoblotting analyses further confirmed the presence of intense immunoreactive bands in the surface fraction from HEK293T cells transfected with OATP1B3-WT or -D11 (Fig. 2C) . On the other hand, the surface fractions from HEK293T cells transfected with OATP1B3-D23 or -D28 displayed immunoreactive bands of much reduced intensities, with OATP1B3-D28 being the lowest (Fig. 2C) control (Fig. 2D ). HEK293T cells expressing OATP1B3-D23 also displayed an enhanced retention of fluorescein by 7-fold, compared to the empty vector control. Despite its markedly decreased level in the surface fraction, OATP1B3-D23 showed substantial fluorescein retention that was inhibited by rifampicin, suggesting that OATP1B3-D23 can function as an efficient transporter for fluorescein even at the low expression level. OATP1B3-D28 showed approximately 3.3-fold increase in fluorescein retention that was inhibited by rifampicin compared to the empty vector control. Taken together, these results suggested that important residue(s)/ motif(s) regulating the plasma membrane trafficking and/or transport activity of OATP1B3 may reside between amino acid positions of 12 and 28 in the N-terminal region.
Point mutations of positively charged amino acids or putative phosphorylation sites had no impact on subcellular localization of OATP1B3
Given that a cluster of positively charged amino acids is often involved in interacting with other proteins [20, 21] , point mutations of Lys (at the positions of 18, 19 and 20) or Arg (at the positions of 22 and 23) residues to Ala were introduced in the sequence of 18 KKKTRR 23 via site-directed mutagenesis (Fig. 3A) . Those point mutations (either at a single site or in combination) had no substantial impact on the extent of surface expression of OATP1B3 ( Fig. 3B and C) . In silico algorithms (KinasePhos and PROSITE)
predicted Ser residues at the positions 13 and 16 to be potentially phosphorylated by Casein kinase II (CK2) and protein kinase C (PKC), respectively. However, point mutations of Ser residues at the positions of 13, 15 or 16 had no impact on the surface expression of OATP1B3 (Fig. 3D) .
3.4. Disruption of putative motifs forming secondary structures (b-turn or a-helix) had no substantial impact on membrane trafficking of OATP1B3
The tetrapeptide b-turn-forming motif located near the N-terminus of human concentrative nucleoside transporter 3 (hCNT3) was shown to play an important role in apical sorting of the protein [22] . When the b-turn forming propensity (D-score) of tetrapeptides within the N-terminal region of OATP1B3-WT was assessed using the residue-coupled model [18] , the sequence of 14 (Fig. 3B ). In addition, the a-helix structure is often considered to be engaged in cell signaling was predicted to be a putative a-helix forming motif by the Phyre2 program (Fig. 4C) . A point mutation of Arg to Pro at the position of 23 had no impact on the levels of OATP1B3 protein in the surface fraction (Fig. 4D) .
Fusion proteins of the N-terminal 50 amino acid sequences of OATP1B3, OATP1B1 or rat Oatp1b2 with a C-terminal myc tag displayed membrane localization
While the N-terminal truncation mutants OATP1B3-D23 and -D28 displayed defective membrane trafficking (Fig. 2) , various point mutations in that region did not alter membrane trafficking of OATP1B3 protein (Figs. 3 and 4) . For the validation purpose, we prepared a construct expressing the C-terminal myc-tag fusion protein composed of the N-terminal 50 amino acids of OATP1B3 (predicted to include the first transmembrane domain) as well as its closely related proteins, OATP1B1 and rat Oatp1b2. Alignment of the N-terminal regions of these transporters displayed a high degree of amino acid sequence identity and similarity (Fig. 5A) . All three fusion proteins containing the N-terminal regions of OATP1B3, OATP1B1 or rat Oatp1b2 were detected in both surface and cytoplasmic fractions (Fig. 5B) . These results indicated that the importance of the N-terminal sequences in driving surface membrane expression of the protein is conserved among the OATP1B subfamily members. To further pinpoint the specific sequence(s) in this N-terminal region, additional fusion constructs with the first 11 or 23 amino acids deleted from the OATP1B3 Nterminal only construct were prepared. Our results indicated that the fusion protein containing amino acids 12-50 was effectively localized to the membrane, but the fusion protein containing amino acids 24-50 was not detectable in surface fractions (Fig. 5C ).
Discussion
Despite the important role of OATP1B3 in influencing drug uptake into hepatocytes and subsequent disposition, our understanding has been very limited regarding molecular mechanisms regulating the expression and membrane trafficking of OATP1B3. The non-membranous expression pattern of cancer-type OATP1B3 lacking the N-terminal 28 amino acids provided an intriguing clue about probing the membrane trafficking mechanisms of OATP1B3 [11] , but no experimental proof was available. In our current study, we were able to confirm the importance of the N-terminal region in membrane trafficking of OATP1B3. We report for the first time that the N-terminal 50 amino acid sequences of OATP1B3 and other closely related OATP1B subfamily members are sufficient for membrane localization. In our efforts to identify the responsible residue(s)/structural motif(s) in the N-terminal region, we utilized various constructs harboring mutations in individual amino acids or regions with putative secondary structures. Our current results however did not yield key individual amino acid(s)/motif(s), suggesting that a complex interplay may be involved. Our current findings should facilitate future efforts to identify the mechanisms regulating the trafficking of OATP1B3 and related transporter proteins. The members of the OATP1B subfamily display considerable amino acid sequence identity (> 60%) as well as their shared substrate specificity [24] . Our results indicated that the importance of the N-terminal region in membrane trafficking is also conserved among the members of the OATP1B subfamily (i.e., OATP1B3, OATP1B1, rat Oatp1b2). We speculated that the amino acid sequences conserved among these transporters may be involved in the common regulatory mechanisms of membrane trafficking. In that regard, the conserved sequence of 30 FLAALS 35 was modified, but no impact on the extent of membrane trafficking was noted (data not shown). In further attempts to verify the importance of the N-terminal region, we prepared a fusion construct containing the amino acid region 12 to 50 of OATP1B3 (i.e., deletion of the first 11 amino acids, Fig. 5C ). Our results indicated that the fusion protein containing N-terminal amino acids 12-50 was effectively localized to the membrane (Fig. 5C ). Further deletion up to amino acid position 23 displayed detectable signals in cytoplasmic fractions, not in surface fractions (Fig. 5C ). Taken together, these results supported that the N-terminal 11 amino acids were dispensable in OATP1B3 membrane trafficking. It has been reported that post-translational modifications such as glycosylation and phosphorylation play a role in regulating the membrane trafficking and activity [25] [26] [27] [28] [29] . In all three cell lines tested, the surface fraction contained the OATP1B3 protein with apparent molecular sizes greater than the cytoplasmic fraction (Fig. 1) . These results are consistent with the previous reports showing that OATP1B3 protein located on the plasma membrane is extensively glycosylated [11, 30] . Using the fusion protein of the N-terminal 50 amino acids, we attempted to investigate whether the glycosylation consensus sequence is included in the N-terminal region. Our results however showed no detectible shift in the electrophoretic mobility upon the incubation of the N-terminal fusion protein of OATP1B3 or OATP1B1 with N-glycosidase F (PNGase F) (data not shown). Similarly, no detectable level of phosphorylation was observed in the N-terminal fusion proteins, regardless of the treatment with the protein kinase C (PKC) activator, phorbol-12-myristate-13-acetate (PMA) (data not shown). Further investigations may be warranted to examine the potential role of post-translational modifications in trafficking of OATP1B3, perhaps by employing different experimental conditions (e.g., human sandwich-cultured hepatocytes) and detection methods with greater sensitivities as suggested by Powell et al. [28] .
Our results from the N-terminal deletion constructs of OATP1B3 indicated the mutants lacking the N-terminal region (in particular, amino acids 12-28) have much reduced expression levels in both cytosolic and surface membrane fractions compared to OATP1B3-WT or -D11. In our previous report [11] , similar observations were made with OATP1B3-D28 and its expression level was substantially increased by the proteasome inhibitor epoxomicin, but not by the lysosomal inhibitor ammonium chloride. In those experiments, the expression plasmid for a green fluorescent protein (GFP) was co-transfected with OATP1B3-WT or -D28 and we observed comparable fluorescent signals, supporting comparable transfection efficiencies. However, it is possible that other mechanisms including translation efficiency may still play a role and that defective maturation/trafficking of the OATP1B3 protein may well be linked to enhanced protein degradation. In recent years, several investigations including those from our laboratory attempted to address why and how cancer cells express cancer-type OATP1B3 (OATP1B3-D28) with much reduced membrane trafficking and transport activity [11, 13, 31, 32] . It has been certainly intriguing that OATP1B3-WT is almost exclusively expressed in normal hepatocytes and that cancerous cells of various non-hepatic organs express cancer-type OATP1B3, but not OATP1B3-WT. It should be noted that earlier reports relied on the detection methods that do not distinguish the two types, but the recent investigations detected each type separately and indicated that OATP1B3-WT is not detected in cancer cells from non-hepatic organs [11, 13, 33] . Given the lack of OATP1B3-WT in cancer cells derived from non-hepatic tissues, it is unlikely that OATP1B3-D28 expressed in those organs would interfere with the activity of OATP1B3-WT or reduce the uptake of endogenous substrates. The OATP1B3-D28 protein displayed a detectable transport activity, albeit substantially attenuated compared to OATP1B3-WT (Fig. 2D) . Thus, we cannot rule out the possibility that cancer-type OATP1B3 may facilitate the uptake of certain endogenous substrates (e.g., estrone-3-sulfate) conferring growth/survival advantages to cancer cells or have functions independent of its transport activity [34] . These questions certainly warrant further investigations.
In conclusion, we confirmed that the N-terminal region is important for membrane trafficking of OATP1B3 and its closely related OATP1B subfamily transporters. The current findings should facilitate future investigations of the mechanisms/motifs involved in the regulation and membrane trafficking of these important transporter proteins.
